timothy sykes logo
Moderna Stock Explodes As Melanoma Vaccine Trial Delivers Breakthrough Thumbnail
G Google News

Moderna Stock Explodes As Melanoma Vaccine Trial Delivers Breakthrough

ELLIS HOBBS•UPDATED AUG. 25, 2026, 12:32 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Moderna Inc. stocks have been trading up by 12.86 percent after strong mRNA pipeline progress fueled bullish investor sentiment.

Key Takeaways

  • Late-stage INTerpath-001 melanoma trial showed intismeran autogene plus Keytruda hit primary and key secondary survival endpoints, the first positive Phase 3 readout for an mRNA cancer therapy.
  • Shares of MRNA ripped as much as 177% intraday, briefly making Moderna the biggest gainer in the S&P 500 and forcing a wholesale market re-rating.
  • Bank of America hiked its MRNA price target from $40 to $170 and upgraded to Neutral, calling the melanoma data a “watershed moment” that eases capital worries.
  • William Blair moved MRNA to Outperform after the data, highlighting how the cancer franchise could diversify revenue away from COVID products.
  • Across multiple reports, Moderna and Merck stressed that intismeran autogene plus Keytruda improved recurrence-free and distant metastasis-free survival with no new safety issues in resected stage IIB–IV melanoma.

Candlestick Chart

Live Update At 12:31:56 EDT: On Tuesday, August 25, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 12.86%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Traders watching MRNA’s chart see a textbook re-rating in real time. Just days ago, Moderna traded near $60. By 2026/08/19, shares spiked to an intraday high of $176.66 and closed at $174.38. Since then, the stock has churned in a higher range, finishing 2026/08/25 at $156.75 after tagging $159.47. That’s still well above pre-news levels, signaling strong dip-buying interest.

Under the hood, MRNA is not a clean earnings story yet. Quarterly revenue sits around $145M, down sharply from the COVID boom years, and the company printed a net loss of about $782M with EBITDA at roughly -$734M. Profit margins are deeply negative, and free cash flow in the latest quarter was about -$563M.

More Breaking News

But Moderna’s balance sheet gives it runway. The company holds about $5.1B in cash and short-term investments, a current ratio near 2.3, and modest long-term debt of roughly $1.2B. Valuation is rich, with a price-to-sales ratio around 25.7 and price-to-book above 8, telling traders the market is now paying up for MRNA’s mRNA oncology optionality rather than current earnings.

Why Traders Are Watching MRNA’s Melanoma Breakout

MRNA just delivered the kind of catalyst most biotech traders wait years for. Together with Merck, Moderna reported that its individualized mRNA cancer vaccine, intismeran autogene (V940/mRNA-4157), combined with Keytruda, hit both primary and key secondary endpoints in the Phase 3 INTerpath-001 trial in resected stage IIB–IV melanoma. The combo improved recurrence-free survival and distant metastasis-free survival, and importantly, no new safety issues surfaced.

That makes this the first positive Phase 3 readout for any mRNA-based cancer therapy. For traders, that matters more than any single quarter’s revenue. It validates the MRNA oncology platform, not just one drug. The market understood this instantly. Reports show MRNA up 54% when the news first broke, then nearly doubling as more details came out. At one point, shares rallied 142% and later 177%, turning Moderna into the biggest gainer in the S&P 500 and lifting the entire healthcare sector.

Analysts chased the move. Bank of America went from Underperform to Neutral, lifting its MRNA price target from $40 straight to $170 and calling the data a watershed moment that broadens Moderna beyond infectious disease and eases capital concerns. William Blair upgraded MRNA to Outperform after the interim readout, noting the melanoma win helps diversify revenue away from COVID. For active traders, that shift in Street narrative—from COVID one-hit wonder to oncology platform name—is the real story powering this momentum.

Conclusion

For short-term traders, MRNA has turned into a high-powered momentum vehicle. The daily chart shows a vertical move from the $60s to the $170s, followed by wide intraday ranges around $150–$160. Five‑minute candles on 2026/08/25 reveal steady buying on dips from the mid‑$140s through the high‑$150s, a classic sign that funds are building or defending positions after a thesis-changing catalyst.

On the fundamental side, MRNA is still burning cash, with negative operating cash flow and steep losses as it builds out its pipeline. But the INTerpath-001 result removes a big chunk of platform risk. It shows that Moderna’s personalized mRNA cancer approach can deliver statistically significant and clinically meaningful survival benefits when paired with Merck’s Keytruda, and do it without new safety red flags. That’s why traders were willing to re-price the entire company in a single session.

This is where discipline matters. As Tim Sykes loves to remind traders, “The market doesn’t care about your opinion, only about price action and catalysts.” At the same time, his broader trading philosophy still applies here: As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. MRNA now has one of the biggest biotech catalysts of the year, plus analyst upgrades and sector attention behind it. For educational and research purposes, traders can study how the stock digests this move—watching volume, support zones, and failed breakouts—to learn how true, thesis-changing news reshapes both a chart and a company’s long-term narrative.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”